Tech Company Financing Transactions
MaxCyte Funding Round
Private investors participated in a $760.3 thousand capital raise for MaxCyte. This venture round was announced on 9/30/2016.
Transaction Overview
Company Name
Announced On
9/30/2016
Transaction Type
Venture Equity
Amount
$760,308
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. 9 investors participated in the offering. The amount may include options, warrants or other securities. Contact technology company for investment details, if applicable. Not an offer or solicitation for the sale of securities or debt. SEC regulatory filing.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
22 Firstfield Rd. 110
Gaithersburg, MD 20878
USA
Gaithersburg, MD 20878
USA
Phone
Website
Email Address
Overview
MaxCyte is a clinical-stage cell therapeutics company with a growing pipeline of proprietary and partnered drug candidates.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Douglas Doerfler
Chief Financial Officer
Ronald Holtz
Chief Medical Officer
Claudio Ullmann
VP - Customer Service
James Brady
VP - General Counsel
Maher Masoud
VP - Operations
Brad Calvin
VP - Regulatory Affairs
Kathryn Wekselman
VP - Sales
Thomas Ross
Browse more venture capital transactions:
Prev: 9/30/2016: Karamba Security venture capital transaction
Next: 9/30/2016: Lingumi venture capital transaction
Share this article
Where The Data Comes From
We do our best to record all VC transactions involving tech companies. VC investment data records reported here are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs